Save time and get answers to complex questions with AI chat
Bivalirudin manufacturer?What's the recommended schedule for lurbinectedin side effect checks?Dabrafenib mesylate when the patent is expiring in india?Dabrafenib and trametinib cost?Somatuline depot patent expiry date?
See the DrugPatentWatch profile for Vimizim
Yes—when Sanofi launched Vimizim (alglucosidase‑alpha) for Pompe disease in 2014, the U.S. launch price was roughly $380,000 per year (about $380 k for the first treatment course). Prices have fluctuated since then and can differ by payer, region, and reimbursement negotiations, but $380 k was the approximate starting point at launch.
Other Questions About Vimizim :